NasdaqGS:KRYSBiotechs
FDA PreCheck Could Speed Up These 3 U.S. Biopharma Stocks
The FDA’s new PreCheck pilot is putting fresh attention on U.S. biopharmaceutical manufacturing stocks, as faster facility reviews could reshape how quickly companies bring complex therapies to market. With select facilities from Eli Lilly, Regeneron and others lined up for accelerated oversight, investors are watching which businesses might gain from quicker approvals, added capacity and stronger onshore supply chains, and which could be left waiting. This article walks through 3 stocks from...